Risk Factors of Deep Vein Thrombosis by Mustafa Sirlak et al.
Selection of our books indexed in the Book Citation Index 
in Web of Science™ Core Collection (BKCI)
Interested in publishing with us? 
Contact book.department@intechopen.com
Numbers displayed above are based on latest data collected. 
For more information visit www.intechopen.com
Open access books available
Countries delivered to Contributors from top 500 universities
International  authors and editors
Our authors are among the
most cited scientists
Downloads
We are IntechOpen,
the world’s leading publisher of
Open Access books
Built by scientists, for scientists
12.2%
122,000 135M
TOP 1%154
4,800
1 
Risk Factors of Deep Vein Thrombosis 
Mustafa Sirlak, Mustafa Bahadir Inan, 
 Demir Cetintas and Evren Ozcinar 
Ankara University School of Medicine, Department of Cardiovascular Surgery, 
 Ankara, 
Turkey 
1. Introduction 
Deep vein thrombosis is a clinical challenge for doctors of all disciplines. It can complicate 
the course of a disease but might also be encountered in the absence of precipitating 
disorders. Thrombosis can take place in any section of the venous system, but arises most 
frequently in the deep veins of the leg. Long-term morbidity due to post-thrombotic 
syndrome is common and can be substantial. The major concern, however, is embolisation 
of the thrombus to the lung, which can be fatal. Deep vein thrombosis is highly prevalent 
and poses a burden on health economy. The disorder and its sequelae are also among the 
best examples of preventable diseases. Relevant data for the frequency of deep vein 
thrombosis derive from large community-based studies because they mainly reflect 
symptomatic rather than asymptomatic disease. In a systematic review, the incidence of first 
deep vein thrombosis in the general population was 0·5 per 1000 person-years.1 The 
disorder is rare in children younger than 15 years,2,3 but its frequency increases with age, 
with incidence per 1000 person-years of 1·8 at age 65–69 years and 3·1 at age 85–89 years.4 
Two-thirds of first-time episodes of deep vein thrombosis are caused by risk factors, 
including surgery, cancer, immobilisation, or admission for other reasons.5,6 Risk for first 
deep vein thrombosis seems to be slightly higher in men than in women.6,9 In a population-
based cohort study, the age-adjusted incidence of first venous thromboembolism was 1·3 
per 1000 person-years in men and 1·1 per 1000 person-years in women.2 It is noteworthy 
that the risk for recurrence of this disorder is higher in men than in women.6,10 
Conditions associated with increased risk for deep vein thrombosis 
Advancing age 
Obesity 
Previous venous thromboembolism 
Surgery 
Trauma 
Active cancer 
Acute medical illnesses – eg, acute myocardial infarction, heart failure, respiratory failure, 
infection 
Inflammatory bowel disease 
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Antiphospholiped syndrome 
Dyslipoproteinaemia 
Nephrotic syndrome 
Paroxysmal nocturnal haemoglobinuria 
Myeloproliferative diseases 
Behçet’s syndrome 
Varicose veins  
Superficial vein thrombosis 
Congenital venous malformation 
Long-distance travel 
Prolonged bed rest 
İmmobilisation 
Limb paresis 
Chronic care facility stay 
Pregnancy/Puerperium 
Oral contraceptives 
Hormone replacement theraphy 
Heparin-induced thrombocitopenia 
Other drugs 
Chemotheraphy 
Tamoxifen 
Thalidomide 
Antipsychotics 
Central Venous catheter 
Vena cava filter 
İntravenous drug abuse 
Rudolph Virchow is recognized as the first person to link the development of VTE to the 
presence of at least 1 of 3 conditions: venous stasis, vascular injury, and/or 
hypercoagulability. 11 Each of these factors can alter the delicate hemostatic balance toward 
hypercoagulability and development of thrombosis. Several aspects of surgery can be linked 
to Virchow’s triad. Coleridge-Smith et al12 reported in 1990 that venous stasis occurs during 
general surgery, with veins dilating 22% to 28% in patients undergoing general anesthesia 
and surgery and up to 57% in those who also received an infusion of 1 L of saline during 
surgery. The investigators suggested that it is this intraoperative venous distension that 
underlies the risk for DVT in patients undergoing surgery. They suggested that the venous 
distension is the result of loss of muscle tone that is caused by the muscle relaxants used 
during surgery. Muscle paralysis resulting from regional anesthesia also can lead to venous 
dilatation. These effects can be modified to some extent by the use of graduated 
compression stockings during surgery.13 In a study of 40 patients undergoing surgery of the 
abdomen or neck, the median vein diameter in the extremity studied was 2.6 mm at the 
beginning of surgery in both the control and intervention groups (control group, n = 20; 
median vein diameter, 2.6 mm; interquartile range [IQR], 2.1–3.3 mm; stocking group, n =20; 
median vein diameter, 2.6 mm; IQR, 2.1–3.7 mm). This decreased to a median vein diameter 
of 1.6 mm (IQR, 1.3–2.8 mm) after application of a stocking, whereas vein diameter 
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increased from 2.6 to 2.9 mm (IQR, 2.3– 4.0 mm) in the control group.13 Comerota et al14 
found that in patients undergoing total hip replacement surgery, handling of soft tissue 
(muscle) during surgery leads to venodilation, whereas bone manipulation leads to 
venoconstriction. The venous dilatation that occurs during surgery causes cracks in the 
endothelium, which provides a nidus for thrombosis as the blood coagulation system is 
activated. The researchers also showed that pharmacologic control of venodilation during 
surgery reduced postoperative DVT.14 Microscopic vessel wall damage, 15 such as that 
demonstrated in patients undergoing hip and knee replacement surgeries, also contributes 
to the development of VTE. 16,17 Tissue factor released from the blood vessel wall after 
injury drives thrombus formation,18 which may help explain the increased risk of VTE in 
patients undergoing surgery. The third factor in Virchow’s triad, hypercoagulability, is 
linked to a number of factors, including certain genetic traits. Deficiencies of antithrombin, 
protein C, or protein S, or mutations of factor V Leiden or factor II (prothrombin) G20210A 
genes lead to hypercoagulable states.11 Although these genetic factors account for only a 
small percentage of the total cases of VTE, more than half of all patients with juvenile or 
idiopathic VTE have been identified with an inherited thrombophilic condition.11. Given 
that VTE is the leading preventable cause of in-hospital deaths,19 every patient should be 
screened before other lesser screens are performed (bedsores, risk of falls, nutritional 
evaluation, and so forth). Stated another way— every patient deserves a proper history and 
physical to uncover any possible factors that might increase their risk of a VTE. 
 
Deep vein 
thrombosis 
Pulmonary 
embolism 
 Calf Proximal Clinical Fatal 
Low risk (minor surgery in patients < 40 years 
with no additional risk factors) 
2% 0-4% 0-2% <0,01% 
Moderate risk (minor surgery and additional 
risk factor 
10-20% 2-4% 1-2% 0,1-0,4% 
High risk (surgery in patients > 60 years or age 
40-60 years with additional risk factors (previous 
venous thromboembolism, cancer, thrombophilia)
20-40% 4-8% 2-4% 0,4-1,0% 
Highest risk (surgery in patients with multiple 
risk factors [age > 40 years, cancer, previous 
venous thromboembolism]: hip or knee 
arthroplasty, hip fracture surgery; major trauma – 
spinal cord surgery) 
40-80% 10-20% 4-10% 0,2-5% 
Modified from reference 16 with permission of the American College of Chest Physicians. 
Table 1. Risk of venous thromboembolism in surgical patients without prophylaxis 
In 1992, the Thromboembolic Risk Factors (THRIFT) Consensus Group identified acquired 
risk factors for VTE.20 Sixteen years later, the most recent update of the American College of 
Chest Physicians (ACCP) guidelines for VTE prophylaxis reveals essentially the same risk 
factors for VTE as those identified by THRIFT, with the addition of a few new ones, 
including acute medical illness, and the removal of smoking as a separate risk factor (Table 
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1). 19 The incidence of VTE increases dramatically in tandem with the number of risk factors 
identified in patients.11,21 Most hospitalized patients have at least one risk factor for VTE, 
and the most recent ACCP review of VTE estimated that approximately 40% have 3 or more 
risk factors.19 These include fracture (hip or leg), hip or knee replacement, major general 
surgery, major trauma, and spinal cord injury,11 as well as a history of VTE,11 
thrombophilia, 11 inflammatory bowel disease,22 postoperative infection, 19 and cancer.23 
Bed rest for more than 72 hours,11,24 use of hormones,11 and impaired mobility11 are 
additional risk factors. Many of these factors are not simple binary (ie, yes/no) risks. For 
example, age is a significant risk factor, with the risk approximately doubling with each 
decade beyond age 40.11,25 It is not sufficient to use a single age cut-off level to define high 
or low risk.11 Similarly, the incidence of VTE increases with length of surgery.26,27 In 
addition, Sugerman et al28 found higher rates of VTE in obese patients (mean body mass 
index, 61) who also had venous stasis syndrome; a simple cut-off level based on a definition 
of obesity would not capture this increased risk. In fact, Anderson and Spencer11 suggest 
that the association of risk of VTE and weight alone is a weak one. As noted earlier, 
hospitalized patients usually have at least 1 risk factor for VTE, and more than a third of 
hospitalized patients have 3 risk factors or more.19 Risk factor weighting can be used to 
calculate the risk for an individual patient, and the results may be used to determine several 
aspects of prophylaxis, such as the length of prophylaxis (including out-of-hospital 
prophylaxis), selection of prophylactic agent, timing of first dose, and the need for combined 
use of physical and pharmacologic methods. 
Risk assessment typically has taken 1 of 2 approaches, group risk assessment or individual 
risk assessment. The group risk assessment approach assigns patients to one of a few broad 
risk categories, whereas individual risk assessment seeks to define risk more accurately by 
using individualized risk scores.19 The system recommended by the 2001 ACCP guidelines 
used a group risk assessment in which the type of surgery (“major” vs “minor”), age 
bracket, and presence of additional risk factors were used to assign patients to 1 of 4 risk 
groups29; however, this was based on older studies, arbitrary age cut-off levels, and inexact 
definitions.19 The ACCP has refined this recommendation with a newer one in which 
patients are assigned 1 of 3 VTE risk levels based on type of surgery, patient mobility, 
overall risk of bleeding, and moderate/high risk of VTE based on the presence of additional 
risk factors 19 As the investigators note, this group risk assessment approach ignores the 
substantial variability in patient-specific risk factors, but it does take into account what they 
view as the principal risk factor (surgery vs acute medical illness). This approach is most 
appropriate for patients who fit the criteria of the randomized clinical trials that were used 
to develop the model; the investigators include a disclaimer for patient groups that have not 
been included in clinical trials or for types of patients who have not been tested.19 However, 
the group risk assessment approach recommended by the ACCP may not be appropriate for 
all individual patients.30 Out-of-hospital prophylaxis is not addressed except for a few very 
high risk groups (major cancer surgery, total joint replacement).19 It may be more 
appropriate to use the individual risk assessment approach to identify and evaluate all 
possible risk factors to determine the true extent of risk for a patient.30 The ACCP 
guidelines, in fact, point out that “specific knowledge about each patient’s risk factors for 
VTE” is an essential component of the decision-making process when prescribing 
thromboprophylaxis. 19 Also, if many risk factors are present and a planned procedure is 
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based on a quality-of-life decision rather than a critical medical need, the patient may come 
to a different decision about whether to proceed.30 A common misconception among 
physicians is that individual risk assessment takes longer and is more cumbersome than 
group risk assessment. However, individual assessment can be accomplished with, for 
example, a simple assessment form that merely captures information from the history and 
physical examination of the patient. 
Among all patients with PE in the PIOPED II trial 94% had 1 or more of the following 
assessed risk factors: bed rest within the last month of 3 days or more, travel within the last 
month of 4 hours or more, surgery within 3 months, malignancy, past history of DVT or PE, 
trauma of lower extremities or pelvis, central venous instrumentation within 3 months, 
stroke, paresis or paralysis, heart failure or chronic obstructive pulmonary disease 
(COPD).31 Immobilization of only 1 or 2 days may predispose to PE, and 65% of those who 
were immobilized were immobilized for 2 weeks or less.32 
2. Obesity and height  
Investigations that reported an increased risk for VTE caused by obesity have been criticized 
because they failed to control for hospital confinement or other risk factors.33 High 
proportions of patients with VTE have been found to be obese,13,34 but the importance of 
the association is diminished because of the high proportion of obesity in the general 
population.35 Some investigations showed an increased risk ratio for DVT or PE in obese 
women,21,36,38 but data in men were less compelling. The Nurses’ Health Study showed 
that the age-adjusted risk ratio for PE women with a body mass index (BMI, calculated as 
weight in kilograms divided by the square of height in meters) 29.0 kg/m2 or higher was 3.2 
compared with the leanest category of less than 21.0 kg/m2.36 The Framingham Heart 
Study showed that metropolitan relative weight was significantly and independently 
associated with PE among women, but not men.39 However, the Study of Men Born in 1913 
showed that men in the highest decile of waist circumference (>100 cm) had an adjusted 
relative risk for VTE of 3.92 compared with men with a waist circumference less than 100 
cm.40 Among 1272 outpatients (men and women), the odds ratio for DVT, comparing obese 
(BMI> 30 kg/m2) with nonobese patients, was 2.39.41 Others showed a similar odds ratio 
for DVT of 2.26 compared with nonobese patients.37 BMI correlated linearly with the 
development of PE in women.42 On the other hand, the Olmsted County, Minnesota case-
control study found no evidence that current BMI was an independent risk factor for VTE in 
men or women.33,43 Others did not show obesity to be a risk for VTE in men.21,38 Analysis 
of the huge database of the National Hospital Discharge Survey44 showed compelling 
evidence that obesity is a risk factor for VTE.45 Among patients hospitalized in short-term 
hospitals throughout the United States, in whom obesity was coded among the discharge 
diagnoses but not defined, 91,000 of 12,015,000 (0.8%) had PE.45 Among hospitalized 
patients who were not diagnosed with obesity, PE was diagnosed in 2,366,000 of 691,000,000 
(0.3%). DVT was diagnosed in 243,000 of 12,015,000 (2.0%) of patients diagnosed with 
obesity, and in 5,524,000 of 691,000,000 (0.8%) who were not diagnosed with obesity. The 
relative risk of PE, comparing obese patients with nonobese patients, was 2.18 and for DVT 
it was 2.50.45 The relative risks for PE and DVT were age dependent. Obesity had the 
greatest effect on patients less than 40 years of age, in whom the relative risk for PE in obese 
patients was 5.19 and the relative risk for DVT was 5.20.45 The higher relative risk of obesity 
in younger patients may have reflected that younger patients uncommonly have multiple 
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confounding- associated risk factors, which make the risk of obesity inapparent. Previous 
investigators used several indices of obesity including a BMI greater than 35 kg/m2 as well 
as BMI 30 to 35 kg/m2,46 BMI 29 kg/m2 or greater,36 weight more than 20% of median 
recommended weight for height,13 and for men, waist circumference 100 cm or greater.40 It 
is likely that all patients diagnosed with obesity in the National Hospital Discharge Survey 
database were obese, irrespective of the criteria used. However, some obese patients may 
not have had a listed discharge diagnosis of obesity, and they would have been included in 
the nonobese group. This situation would have tended to reduce the relative risk of obesity 
in VTE. Various abnormalities of hemostasis have been described in obesity, in particular 
increased plasminogen activator inhibitor-1 (PAI-1).47,48 Other abnormalities of coagulation 
have been reported as well,48 including increased platelet activation,39 increased levels of 
plasma fibrinogen, factor VII, factor VIII, and von Willebrand factor.49 Fibrinogen, factor 
VIIc, and PAI-1 correlated with BMI.50 Regarding height, in the study of Swedish men, 
those taller than 179 cm (5’ 10”) had a 1.5 times higher risk of VTE than men shorter than 172 
cm.51 The Physicians’ Health Study of male physicians also showed that taller men had a 
significantly increased risk of VTE.52 
3. Air travel 
The possibility of VTE after travel is not unique to air travel.53,54 Prolonged periods in 
cramped quarters, irrespective of travel, can lead to PE.55 The term economy class 
syndrome was introduced in 1988,56 but has since been replaced with flight-related DVT in 
recognition that all travelers are at risk, irrespective of the class of travel57 Rates of 
development of PE with air travel lasting 12 to 18 hours have been calculated as 2.6 
PE/million travelers.58 With air travel of 8 hours or longer, 1.65/million passengers had 
acute PE on arrival.59 With 6 to 8 hours of air travel the rate of acute PE on arrival was 
0.25/million and among those who traveled for 6 hours or less none developed acute PE on 
arrival.59 The trend showing increasing rates of PE with duration of travel is compelling, 
but the incidence of DVT was about 3000 times higher in a prospective investigation.60 In a 
prospective investigation of travelers who traveled for 10 hours or longer, 4 of 878 (0.5%) 
developed PE and 5 of 878 (0.6%) developed DVT.60 
4. Varicose veins 
Varicose veins were found by some to be an agedependent risk factor for VTE.43 Among 
patients aged 45 years the odds ratio for VTE was 4.2.43 In patients aged 60 years the odds 
ratio was 1.9 and at aged 75 years, varicose veins were not associated with an increased risk 
of VTE.43 However, others did not find varicose veins to be a risk factor for DVT61 or PE 
found at autopsy.21 
5. Oral contraceptives 
Although the risk of VTE is higher among users of oral estrogen-containing contraceptives 
than nonusers, 62,63 the absolute risk is low.64 An absolute risk of VTE of less than 1/10,000 
patients/y increased to only 3 to 4/10,000 patients/y during the time oral contraceptives were 
used.64 The relative risk for VTE in women using oral contraceptives containing 50 mg of 
estrogen, compared with users of oral contraceptives that contained less than 50 mg was 1.5.65 
The relative risk for VTE in women using oral contraceptives containing more than 50 mg of 
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estrogen, compared with users of oral contraceptives that contained less than 50 mg was 1.7.65 
No difference in the risk of VTE was found with various levels of low doses of 20, 30, 40, and 
50 mg/d.66 With doses of estrogen of 50 mg/d, the rate of VTE was 7.0/ 10,000 contraceptive 
users/y and with more than 50 mg/d, the rate of VTE was 10.0/10,000 oral contraceptive 
users/y.65 However, some found no appreciable difference in the relative risk of VTE in 
relation to low or higher estrogen doses.67 Reports of the risk of VTE in relation to the 
duration of use of oral contraceptives are inconsistent. Some showed relative risks increased as 
the duration of use of estrogen-containing oral contraceptives increased.68 The relative risks 
were 0.7 in women who used oral contraceptives for less than 1 year, 1.4 for those who used 
oral contraceptives for 1 to 4 years and 1.8 in those who used it for 5 years or longer.68 Others 
showed the opposite effect, with a decreasing relative risk with duration of use.66 The relative 
risk for DVT or PE was 5.1 with use for less than 1 year, 2.5 with use for 1 to 5 years, and 2.1 
with use for longer than 5 years.66 Some showed the risk to be unaffected by the duration of 
use.67 A synergistic effect of oral contraceptives with obesity has been shown.69,71 The odds 
ratio of DVT in obese women (BMI _30 kg/m2) who were users of oral contraceptives ranged 
from 5.2 to 7.8 compared with obese women who did not use oral contraceptives37,69,71 and 
among women with a BMI 35 kg/m2 or higher, the odds ratio was 3.1 compared with 
similarly obese nonusers of oral contraceptives.71 
6. Tamoxifen 
Tamoxifen is a selective estrogen-receptor modulator used for treatment of breast cancer 
and for prevention of breast cancer in high-risk patients.72,74 Among women with breast 
cancer currently being treated with tamoxifen, compared with previous users or those who 
never used it, the odds ratio was 7.1.74 Others found a lower odds ratio of 2.7.43 The odds 
ratio for VTE in women at high risk of breast cancer who received tamoxifen to prevent 
breast cancer was 2.1.73 Others found a hazard ratio of 1.63.72 
7. Hormonal replacement therapy 
There is a 2- to 3-fold increased risk of VTE with the use of hormone replacement therapy in 
postmenopausal women.75,76 Among postmenopausal women who had coronary artery 
disease and received estrogen plus progestin, the relative hazard of VTE was 2.7 compared 
with nonusers.77 Review showed that the risk of VTE is highest in the first year of hormone 
replacement therapy.78 The risk of VTE is increased for oral estrogen alone, oral estrogen 
combined with progestin, and probably for transdermal hormone replacement therapy.78 
8. Congenital hypercoagulable disorders 
8.1 Antithrombin deficiency 
Antithrombin is a serine protease inhibitor of thrombin and also inhibits factors IXa, Xa, XIa, 
and XIIa. Thrombin is irreversibly bound by antithrombin and prevents thrombin’s action 
on fi brinogen, on factors V, VIII, and XIII, and on platelets.79 This anticoagulant is 
synthesized in the liver and endothelial cells, and has a half-life of 2.8 days.80 Antithrombin 
deficiency has a prevalence of 1 : 5000 with more than 100 genetic mutations and an 
autosomal dominant inheritance pattern.81 Homozygotes typically die in utero whereas 
heterozygotes typically have an antithrombin level that is 40 to 70% of normal. 
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Antithrombin deficiency is associated with lower extremity venous thrombosis as well as 
mesenteric venous thrombosis. The most common presentation in those with antithrombin 
deficiency is deep venous thrombosis with or without pulmonary embolism.82 
8.2 Protein C and protein S deficiency 
Protein C is a vitamin K dependent anticoagulant protein that, once activated by thrombin, 
will inactivate factors Va and VIIIa, thereby inhibiting the generation of thrombin.83 
Additionally, activated protein C stimulates the release of t-PA. It is produced in the liver 
and is the dominant endogenous anticoagulant with an eight-hour half-life. Protein C 
deficiency has a prevalence of 1 in 200–300 with more than 150 mutations and an autosomal 
dominant inheritance.83,84 
Protein S is also a vitamin K dependent anticoagulant protein that is a cofactor to activated 
protein C. The actions of protein S are regulated by complement C4b binding protein and 
only the free form of protein S serves as an activated protein C cofactor.85 Additionally, 
protein S appears to have independent anticoagulant function by directly inhibiting 
procoagulant enzyme complexes.84,86 The prevalence of protein S defi ciency is about 1 : 500 
with an autosomal dominant inheritance. 
Clinically, protein C and S deficiencies are essentially identical. With homozygous protein C 
and S defi ciencies, infants typically will succumb to purpura fulminans, a state of 
unrestricted clotting and fi brinolysis. In heterozygotes, venous thromboses may occur at an 
early age especially in the lower extremity.87 Thrombosis may also occur in mesenteric, 
renal, and cerebral veins. 
8.3 Factor V Leiden mutation and activated protein C resistance 
Factor V is a glycoprotein synthesized in the liver. With Factor V Leiden, a point mutation 
occurs when arginine is substituted by glutamine at position 506. This point mutation causes 
the activated Factor V to be resistant to inactivation by activated protein C thus causing a 
procoagulant state. 
Clinically, patients may present with deep venous thrombosis in the lower extremities, or 
less commonly in the portal vein, cerebral vein, or superfi cial venous system. 
8.4 Prothrombin G20210 polymorphism 
Prothrombin (Factor II) is a zymogen synthesized in the liver and dependent on vitamin K. 
When prothrombin is activated, it forms thrombin (Factor IIa). A single mutation where 
adenine is substituted for guanine occurs at the 20210 position. The mechanism for 
increased thrombotic risk is not well understood, but individuals with this genetic variant 
have supranormal levels of prothrombin. The mutation is inherited as an autosomal 
dominant trait and is associated with both arterial and venous thrombosis. 
Clinically, patients may present with deep venous thrombosis of the lower extremity, 
cerebral venous thrombosis, as well as arterial thrombosis. The risk of thrombosis increases 
in the presence of other genetic coagulation defects and with acquired risk factors.88,84 
www.intechopen.com
 
Risk Factors of Deep Vein Thrombosis 
 
9 
8.5 Hyperhomocysteinemia 
Homocysteine is an amino acid formed during the metabolism of methionine and may be 
elevated secondary to inherited defects in two enzymes that are part of the conversion of 
homocysteine to cysteine. The two enzymes involved are N5,N10–methylene 
tetrahydrofolate reductase (MTHFR) or cystathionine beta-synthase. 
Hyperhomocysteinemia has been shown to increase the risk of atherosclerosis, 
atherothrombosis, and venous thrombosis. Elevated plasma homocysteine levels cause 
various dysfunctions of endothelial cells leading to a prothrombotic state. 
Hypercoagulable syndromes include inherited and acquired thrombophilias. The former is 
discussed in detail in the article by Weitz in this issue. The latter includes the 
antiphospholipid syndrome, heparin-induced thrombocytopenia, acquired 
dysfibrinogenemia, myeloproliferative disorders, and malignancy. Myeloproliferative 
disorders and malignancy are described elsewhere in this article. Regarding the 
antiphospholipid syndrome, antiphospholipid antibodies are associated with both arterial 
and venous thrombosis.89 The most commonly detected subgroups of antiphospholipid 
antibodies are lupus anticoagulant antibodies, anticardiolipin antibodies and anti-b2-
glycoprotein I antibodies.90 DVT, the most common manifestation of the antiphospholipid 
syndrome, occurs in 29% to 55% of patients with the syndrome, and about half of these 
patients have pulmonary emboli.91,92 The risk of heparin-associated thrombocytopenia is 
more duration related than dose related. Heparin-associated thrombocytopenia occurs more 
frequently with unfractionated heparin when used for an extended duration than with 
LMWH used for an extended duration.93 When used for prophylaxis, there was a higher 
prevalence of heparin-associated thrombocytopenia inthose receiving unfractionated 
heparin (1.6%, 57 of 3463) than in those receiving LMWH (0.6%, 23 of 3714).93 However, 
treatment resulted in only a small difference in the prevalence of heparinassociated 
thrombocytopenia comparing unfractionated heparin (0.9%, 22 of 2321) with LMWH (0.6%, 
18 of 3126).93 Acquired dysfibrinogenemia occurs most often in patients with severe liver 
disease.94 The impairment of the fibrinogen is a structural defect caused by an increased 
carbohydrate content impairing the polymerization of the fibrin, depending on the degree of 
abnormality of the fibrinogen molecule.94 
9. Heart failure 
Congestive heart failure (CHF) is considered amajor risk factor for VTE.13,41,61,95,96 Among 
patients with established CHF, those with lower ejection fractions had a higher risk of 
thromboembolic event.97,98 However, some investigators did not evaluate CHF among the 
risk factors for VTE.99 The reported frequency of PE in patients with heart failure has ranged 
widely from 0.9% to 39% of patients. 13,97,98,100,101 The reported frequency of DVT in patients 
with CHF also ranged widely from 10% to 59%.13,41,61 The largest investigation was from the 
National Hospital Discharge Survey.102 Among 58,873,000 patients hospitalized with heart 
failure in short-stay hospitals from 1979 to 2003, 1.63% had VTE (relative risk 5 1.47).102 The 
relative risk for VTE was highest in patients less than 40 years old (relative risk 5 6.91). Some 
showed the lower the ejection fraction, the greater the risk of VTE.103 Among 755,807 adults 
older than 20 years with heart failure who died from 1980 to 1998, PE was listed as the cause 
of death in 20,387 (2.7%).104 Assuming that the accuracy of death certificates was only 
26.7%,105 the rate of death from PE in these patients may have been as high as 10.1%. 
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Therefore, the estimated death rate from PE in patients who died with heart failure was 3% 
to 10%. CHF seems to be a stronger risk factor in women. Dries and colleagues97 reported a 
higher proportion of PE in women (24%) compared with men (14%). We too showed a 
higher relative risk of PE and of DVT in women with CHF than in men.102 Although these 
data seemcompelling, multivariate logistic analysis failed to identify CHF as an independent 
risk factor for DVT or PE.43 However, it was a risk factor for postmortem VTE that was not a 
cause of death.43 In one study of pediatric patients with dilated cardiomyopathy awaiting 
transplant the incidence of pulmonary embolism was 13.9% 106. 
Heart failure is the second most common risk factor for VTE in hospitalized patients, as 
shown in ENDORSE.107 
10. COPD 
Hospitalized patients with exacerbations of COPD, when routinely evaluated, showed PE in 
25% to 29%.108,109From 1979 to 2003, 58,392,000 adults older than 20 years were hospitalized 
with COPD in short-stay hospitals in the United States.110 PE was diagnosed in 381,000 
(0.65%) and DVT in 632,000 (1.08%).110 The relative risk for PE in adults hospitalized with 
COPD was 1.92 and for DVT it was 1.30. Among those aged 20 to 39 years with COPD, the 
relative risk for PE was 5.34. Among patients with COPD aged 40 to 59 years, the relative risk 
for PE decreased to 2.02, and among patients aged 60 to 79 years the relative risk for PE was 
1.23.110 The relative risk for DVT was also higher in patients with COPD aged 20 to 39 years 
(relative risk 5 2.58) than in patients aged 40 years or older (relative risk 0.92-1.17, depending 
on age).110 In young adults, other risk factors in combination with COPD are uncommon, so 
the contribution of COPD to the risk of PE becomes more apparent than in older patients. 
Although these data strongly suggest that COPD is a risk factor for PE and DVT, multivariate 
logistic analysis did not identify it as an independent risk factor.43 Others, with univariate 
analysis, did not identify COPD as a risk factor.61 
Neuhaus et al. 111 found pulmonary emboli in 27% of 66 autopsies performed in patients 
who had respiratory failure (not only as a decompensation of COPD) and died after 
admission to a Respiratory Intensive Care Unit. 
The largest study was conducted by Schonhofer and Kohler 112 on a population of 196 
patients admitted to a respiratory intensive care unit. The authors found a DVT rate of 
10.7% as assessed by US. The majority (86%) of cases were asymptomatic and, interestingly, 
almost all major clinical variables (such as age, weight, severity of dyspnea, lung function, 
situation of blood gases) failed to predict patients who were more likely to develop DVT. 
11. Stroke 
There is considerable evidence that in spinal cord injury patients interruption of neurologic 
impulses and the ensuing paralysis cause profound metabolic changes in blood vessels 
accountable for venous thrombosis. 
Vascular adaptations to inactivity and muscle atrophy, rather than the effect of a 
nonworking leg-muscle pump and sympathetic denervation, cause thrombosis, indicating 
that thrombosis established through venous incompetence cannot be reversed by 
anticoagulation alone. 
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Spinal cord injuries with paralysis result in an immobile state with retardation of the blood 
flow caused by the relaxation of muscle and the atony of blood vessels. It is not surprising 
that spinal cord injuries are frequently complicated by the development of venous 
thrombosis, which is inevitably linked to hospitalization, immobilization, vein wall damage, 
stasis, and hypercoagulability. Deep vein thrombosis and pulmonary emboli remain the 
major complications in spinal cord injuries below the C2 through T12 vertebrae associated 
with motor complete or motor nonfunctional paralysis. 113,114,115,116,117,118,119 Two surprising 
findings set spinal cord injury apart from other risk factors for venous thrombosis: incidence 
of leg DVT and pulmonary embolism in spinal cord injury is three times higher than in the 
general population. 
Patients with stroke are at particular risk of developing DVT and PE because of limb 
paralysis, prolonged bed rest, and increased prothrombotic activity.120 Among 14,109,000 
patients with ischemic stroke hospitalized in short-stay hospitals from 1979 to 2003, VTE 
was diagnosed in 165,000 (1.17%).121 Among 1,606,000 patients with hemorrhagic stroke, 
the incidence of VTE was higher (1.93%). 
Among patients with ischemic stroke who died from 1980 to 1998, PE was the listed cause of 
death in 11,101 of 2,000,963 (0.55%).122 Based on an assumed sensitivity of death certificates 
for fatal PE of 26.7% to 37.2%,105,123 the corrected rate of fatal PE was 1.5% to 2.1%. Death 
rates from PE among patients with ischemic stroke decreased from 1980 to 1998, suggesting 
effective use of antithrombotic prophylaxis. 
12. Cancer 
Cancer is a major risk factor of venous thromboembolism (VTE) 124,125 as defined by deep-
vein thrombosis (DVT) – including central venous catheter (CVC) related thrombosis – or 
pulmonaryembolism (PE), which occur in 4 to 20% of cancer patients 126,127. 
12.1 Cancer-related factors 
12.1.1 Site of cancer 
In studies looking at pooled groups of patients with different types of malignancy, the rate 
of VTE is consistently highest in patients with cancer of the pancreas, stomach, brain, 
kidney, uterus, lung or ovary 128,129,130,131. 
Both large retrospective studies by Stein et al and Chew et al based on discharge claims 
databases reported the highest rates of VTE in patients with pancreatic cancer (4.3% and 
5.3%, respectively). Patients with stomach cancer had the second and third highest risk of 
developing VTE in these studies 128,132. In patients with testicular and lung cancer, those 
with metastases to the liver and brain were shown to have higher rates of VTE compared 
with patients with other sites of metastases 133,134. The rates of VTE for specific types of 
cancer have been reported in many studies. 
12.1.2 Cancer stage 
Multiple studies have shown an increased risk of VTE in patients with advanced-stage 
cancer. In a retrospective study of over 500 000 patients from the California Cancer Registry, 
patients with metastatic cancer stage were twice as likely to have developed VTE in the year 
www.intechopen.com
 
Deep Vein Thrombosis 
 
12
prior to diagnosis of cancer 135. In a population-based case–control study of patients with 
newly diagnosed VTE, including 389 patients with cancer, those with distant metastases had 
a higher risk of VTE (OR 19.8, CI 2.6–149) 136. 
A multicentre retrospective study of VTE in hospitalized cancer patients reported an 
incidence of 10.3% in patients with advanced-stage cancer compared with 5.6% in patients 
with localized disease (P < 0.0005, OR 1.92, CI 1.21–3.04) 137, and these findings have been 
supported by other large studies in hospitalized cancer patients 138. Other studies in ovarian, 
colorectal, pancreatic, lung and breast cancer support the finding that advanced-stage 
disease increases the risk of cancer- associated VTE 139,140,141,142,143,144. 
12.2 Histology 
In certain types of cancer, higher rates of VTE are found in some histological subtypes 
compared with others. For example, in patients with non-small-cell lung cancer, 9.9% of 
those with adenocarcinoma subtype develop VTE in the first 6 months after diagnosis 
compared with 7.7% with squamous cell carcinoma (HR 1.9, CI 1.7–2.1) 141.Inbreast and 
colon cancer patients, the type of histology does not predict for the incidence of cancer-
associated VTE, but VTE-associated mortality rates are higher in patients with certain 
histological subtypes 141,143. 
12.3 Time after diagnosis 
Several studies have demonstrated that the risk of VTE is highest in the initial time period 
following cancer diagnosis. In a population-based study of patients with thrombosis, the 
risk of developing VTE was highest in the first few months following the initial diagnosis of 
malignancy. A retrospective analysis of over 200 000 cancer patients from the California 
Cancer Registry revealed that the rate of VTE per patient-year in the first year after 
diagnosis of cancer was 3.3, compared with 0.8 in the second year after diagnosis 145. The 
rate of VTE in patients with colon cancer during the first 6 months after diagnosis is 5.0/100 
patient-years, but this drops off dramatically to 1.4/100 patient-years in the next 6- month 
period 143. 
12.4 Chemotherapy 
Chemotherapy is one of the most important factors in VTE risk stratification of cancer 
patients. Large population-based studies in groups of pooled cancer patients have 
demonstrated a significantly increased risk in patients receiving chemotherapy. Heit et al 
used a population-based study of patients with a new diagnosis of VTE, 23% of which had a 
diagnosis of active malignancy, to demonstrate a significantly increased risk of VTE in those 
on chemotherapy (OR 6.5, CI 2.11–20) 146. 
Studies in specific types of cancer and with specific antineoplastic agents have also 
supported the role of chemotherapy in predicting the risk of cancer-associated VTE. Two 
prospective studies of breast cancer patients demonstrated that the risk of VTE in patients 
receiving chemotherapy in addition to tamoxifen or surgery increased two- to seven-fold 
147,148. A recent meta-analysis of breast cancer patients revealed that use of adjuvant 
hormonal therapy was associated with a 1.5–7-fold increased risk of VTE 149. 
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12.5 Surgery 
Surgery is a well-known risk factor for development of VTE in patients without cancer. The 
incidence of DVT in cancer patients undergoing general surgery is estimated at 37% 
compared with 20% in patients without cancer 150. Factors related to immobility, tissue 
destruction and venous stasis are likely to be related to the increased risk of VTE after 
surgery. 
12.6 Indwelling catheters 
Indwelling central venous catheters (CVC) greatly facilitate treatment in cancer patients, but 
they are also associated with complications including a significant risk of catheter-associated 
thrombosis. The incidence of symptomatic catheter-related DVT in adult patients ranges 
from 0.3% to 28%, while the rate of catheter-related DVT assessed by venography is 27–
66%151. 
Studies have not consistently demonstrated an association between use of haematopoietic 
growth factors and risk of cancer-associated VTE. İn a prospective study of ambulatory 
patients receiving chemotherapy, both the use of white cell growth factors and the use of red 
cell growth factors or decreased haemoglobin were independent predictors of VTE in 
multivariate analysis 152. This association was only significant in types of cancer already 
known to have high rates of thrombosis, and it is possible that these agents are used more 
frequently in patients with other markers of poor prognosis or more aggressive disease. 
12.7 Platelet and leukocyte counts 
The authors’ group was the first to identify an elevated prechemotherapy platelet count as a 
significant risk factor for cancer-associated thrombosis 152. In a prospective study of 
outpatients receiving chemotherapy, 21.9% had a platelet count of 350 000/mm3 or more 
prior to starting chemotherapy. The incidence of VTE was 3.98% (1.66% per month) for these 
patients, which was significantly higher than the rate of 1.25% (0.52% per month) for 
patients with a prechemotherapy platelet count of less than 200 000/mm3 (P for trend¼ 
0.0003). The distribution of rechemotherapy platelet counts in patients who subsequently 
developed VTE was significantly higher than that for patients who did not develop VTE (t-
test P ¼0.002, Wilcoxon rank sum test P ¼0.0002). 
12.8 Tissue factor 
Tissue factor (TF), a transmembrane glycoprotein present on subendothelial tissue, platelets 
and leukocytes, is a key component in the initiation of coagulation and may play a role in 
cancer- associated thrombosis 153-155. The authors recently demonstrated a correlation 
between the level of TF expression in pancreatic tumours and subsequent development of 
VTE 156. VTE was four-fold more common (P ¼ 0.04) among patients with high TF-
expressing carcinomas (26.5%) than among patients with low TF-expressing carcinomas 
(5.5%). 
From 1979 to 1999, among 40,787,000 patients hospitalized in short-stay hospitals with any 
of 19 malignancies studied, 827,000 (2.0%) had VTE.157 This was twice the incidence in 
patients without these malignancies.157 The highest incidence of VTE was in patients with 
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carcinoma of the pancreas (4.3%) and the lowest incidences were in patients with carcinoma 
of the bladder and carcinoma of the lip, oral cavity, or pharynx (<0.6% to 1.0%). Incidences 
with cancer were not age dependent.157 Myeloproliferative diseaseand lymphoma were 
associated with relative risks for VTE of 2.9 and 2.5, respectively157 Leukemia was 
associated with a lower relative risk (1.7). Based on death certificates from 1980 to 1998 
among patients who died with cancer, PE was the listed cause of death in 0.21%.158 
Adjustment of the data for the frailty of the diagnosis of fatal PE based on death certificates 
indicated a likely range of 0.31% to 1.97%.158 
13. Pregnancy 
Pregnancy-associated DVT based on data from the National Hospital Discharge Survey was 
diagnosed in 93,000 of 80,798,000 women (0.12%) from 1979 to 1999.151 The rate of 
pregnancyassociated DVT (vaginal delivery and cesarean section) increased from 1982 to 
1999, although the rate of nonpregnancy-associated DVT decreased for most of this period. 
Some showed the rate of pregnancy-associated DVT was twice the rate of nonpregnancy-
associated DVT.159 A 6-fold increase in the rate of thromboembolism during pregnancy and 
the puerperium compared with nonpregnant women has been reported by others.160 
Although the rate of pregnancy-associated DVT was higher than the rate of 
nonpregnancyassociated DVT, the rate of pregnancyassociated PE was lower than  
Pathophysiology of venous thromboembolism during Pregnancy: 
Increased venous distensibility and capacity, with a resultant reduction in the velocity of blood 
flow in the lower limbs, are demonstrable from the first trimester of pregnancy162,163. These 
changes are compounded by a 20–25% increase in the overall circulatory volume during 
pregnancy164. Obstruction of the inferior vena cava by the enlarging gravid uterus may also 
result in increased stasis165. Compression of the left iliac vein by the right iliac artery as they 
cross 166 may explain the preponderance of left leg DVT during pregnancy 161,167. 
Altered levels of coagulation factors have been described both during pregnancy and 
postpartum. Hypercoagulability is thought to be promoted by increases in coagulation 
factors such as fibrinogen, von Willebrand factor, and factor VIII:C 168,169–171, as well as by 
decreases in natural inhibitors of coagulation such as protein S 172 and the development of 
an acquired resistance to the endogenous anticoagulant, activated protein C 173. In addition, 
a reduction in global fibrinolytic activity has been described during pregnancy 174, perhaps 
as a consequence of increases in the levels of plasminogen activator inhibitor 1 (PAI 1) and 
plasminogen activator inhibitor 2 (PAI 2) 174–176, the latter being produced by the placenta. 
Exogenous risk factors also appear to determine the thrombotic risk associated with 
pregnancy. In a retrospective cohort study of unselected consecutive patients with 
confirmed pregnancy-related venous thromboembolism, approximately two-thirds of 
patients had an identifiable acquired risk factor (for example, age over 35 years, intercurrent 
illness, immobility, increased parity or caesarean section) 177. 
The reason for this difference is unknown and could reflect difference of the natural history 
of DVT in pregnancy. It also could reflect a reluctance to expose pregnant women to 
ionizing radiation associated with imaging for PE, resulting in a decreased frequency of 
diagnosis of PE. The rate of pregnancy-associated DVT was higher among women aged 35 
to 44 years than in younger women. The rate of pregnancyassociated DVT among black 
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women was higher than among white women.159,178,179 DVT was more frequent among 
women who underwent cesarean section (104/100,000/y) than those who underwent 
vaginal delivery (47/ 100,000/y).159 VTE in pregnancy is discussed in detail in the article by 
Marik elsewhere in this issue. 
14. Surgery and trauma 
In PIOPED, trauma of the lower extremities was a predisposing factor in 10% of patients 
with PE, and in PIOPED II trauma of the lower extremities or pelvis was a predisposing 
factor in 14%.180,181 Surgery within 3 months of the acute PE was a predisposing factor in 
54% in PIOPED and in 23% in PIOPED II.180,181 The prevalence of VTE following various 
categories of surgery and trauma has been reviewed in detail by Geerts and colleagues182. 
15. Central venous access 
The use of long-term venous access is now an integral component of treatment for patients 
receiving long-term antibiotic administration or hyperalimentation or undergoing 
chemotherapy. Externalized tunneled catheters were introduced almost 30 years ago, but 
required daily cleaning and frequent flushing190,191. On average, deep venous thrombosis 
(DVT) can complicate approximately 2%–6.7% of such port placements192 – 194, although 
literature reports have ranged from 0% to 26%195–198. In 1991, Monreal et al.199 observed that 
4 of 30 consecutive patients with upper extremity deep venous thrombosis (DVT) had PE 
(13.3%), but more importantly, all these 4 occurred in 20 catheter related DVT patients 
(20%), while none of 10 patients with primary upper extremity DVT had PE. 
16. Medical illnesses 
16.1 Inflammatory bowel disease 
The incidence of VTE among hospitalized medical patients with ulcerative colitis was 1.9% 
and the incidence with Crohn disease was lower (1.2%).200 Among medical patients who 
had neither ulcerative colitis nor Crohn disease the incidence was 1.1%.200 The relative risk 
of VTE among patients with ulcerative colitis compared with patients who did not have 
inflammatory bowel disease was 1.9 and with Crohn disease it was 1.2. Among patients 
younger than 40 years with ulcerative colitis, the relative risk of VTE compared with 
patients who did not haveinflammatory bowel disease was 2.96 and in patients younger 
than 40 years with Crohn disease the relative risk was 2.23.200 
16.2 Liver disease 
Patients with chronic liver disease (both alcoholic and nonalcoholic) seem to have a lower 
risk of PE than patients without liver disease,43,201 but data are inconsistent.202 Chronic 
liver disease may result in impaired production of vitamin-K dependent procoagulant 
factors.203 However, decreased production of vitamin-K dependent endogenous 
anticoagulants, such as protein C, protein S, and antithrombin III, may counter the 
hypocoagulability in such patients.203 Other prothrombotic factors may counteract the 
impaired production of vitamin Kdependent procoagulant factors including lupus 
anticoagulant, activated protein C resistance, PT20210A mutation, Factor V Leiden, MTHFR 
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mutation, and increased levels of factor VIII.204 Based on data from the National Hospital 
Discharge Survey, among 4,927,000 hospitalized patients with chronic alcoholic liver disease 
from 1979 to 2006, the prevalence of VTE was 0.6% and among 4,565,000 hospitalized 
patients with chronic nonalcoholic liver disease it was 0.9%.201 The prevalence of VTE was 
higher in those with chronic alcoholic liver disease than with nonalcoholic liver disease, but 
the difference was small and of no clinical consequence.201 
Both showed a lower prevalence of VTE than in hospitalized patients with most other 
medical diseases. It may be that both chronic alcoholic liver disease and chronic 
nonalcoholic liver disease have protective antithrombotic mechanisms although the 
mechanisms differ. 
16.3 Hypothyroidism 
Among 19,519,000 hospitalized patients with a diagnosis of hypothyroidism from 1979 to 
2005, 119,000 (0.61%) had PE (relative risk 5 1.64).205 DVT was diagnosed in 1.36% of 
hypothyroid patients (relative risk 5 1.62).205 The relative risk for PE in patients with 
hypothyroidism was highest in patients younger than 40 years (relative risk 5 3.99) and the 
relative risk for DVT was also highest in patients younger than 40 years (relative risk 5 2.25). 
Hyperthyroidism was not associated with an increased risk for VTE (relative risk 5 0.98). 
16.4 Rheumatoid arthritis 
Rheumatoid arthritis is not generally considered a risk factor for VTE, although abnormalities 
of coagulation factors have been found in patients with rheumatoid arthritis.206,207 Among 
4,818,000 patients hospitalized in short-stay hospitals from 1979 to 2005 with rheumatoid 
arthritis who did not have joint surgery, the incidence of PE was 2.3%, and the relative risk of 
VTE compared with those who did not have rheumatoid arthritis was 1.99.208 Among 
patients younger than 50 years the relative risk was higher (2.13).208 
16.5 Diabetes mellitus 
Among 92,240,000 patients with diabetes mellitus hospitalized from 1979 to 2005, 1,267,000 
(1.4%) had VTE.209 The relative risk for VTE was increased only in patients younger than 50 
years and was highest in patients aged 20 to 29 years (relative risk 5 1.73). In patients with 
diabetes mellitus who did not have obesity, stroke, heart failure, or cancer, compared with 
those who did not have diabetes mellitus and did not have any of these comorbid conditions, 
the relative risk for VTE was 1.52 in patients aged 20 to 29 years and 1.19 in patients 30 to 39 
years. In older patients, the relative risk of VTE in patients with diabetes mellitus was not 
increased.209 Among all adults with diabetes mellitus, the relative risk of VTE was 1.05.209 
16.6 Human immunodeficiency virus 
Among 2,429,000 patients older than 18 years hospitalized in short-stay hospitals from 1990 
through 2005 with human immunodeficiency virus (HIV) infection; the prevalence of VTE 
was 1.7% (relative risk 5 1.21).210 The prevalence of VTE in patients aged 30 to 49 years was 
also 1.7%, but the relative risk compared with patients who did not have HIV infection was 
higher (1.65).210 
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16.7 Nephrotic syndrome 
From 1979 to 2005, 925,000 patients were discharged from short-stay hospitals with 
nephrotic syndrome and 14,000 (1.5%) had DVT (relative risk 5 1.72).211 In patients aged 18 
to 39 years the relative risk for DVT was 6.81.211 Renal vein thrombosis was so uncommon 
that too few were reported to calculate its prevalence. Therefore, PE, if it occurs, is likely to 
be due to emboli from the lower extremities and not the renal vein. 
16.8 Sickle cell disease 
Sickle cell disease does not seem to be a risk factor for DVT.212 Among 1,804,000 patients 
hospitalized in short-stay hospitals with sickle cell disease from 1979 to 2003, 11,000 (0.61%) 
had a discharge diagnosis of DVT, which was not more than in African Americans without 
sickle cell disease (0.81%).212 Among patients with sickle cell disease, a discharge diagnosis 
of PE was made in 0.50% compared with 0.33% who did not have sickle cell disease. 
Regarding patients younger than 40 years, 0.44% had PE, whereas among patients who did 
not have sickle cell disease, 0.12% had PE.212 The higher prevalence of apparent PE in 
patients with sickle cell disease compared with African American patients the same age who 
did not have sickle cell disease, and the comparable prevalence of DVT in both groups, is 
compatible with the concept that thrombosis in situ may be present in many. 
16.9 Systemic lupus erythematosus 
Systemic lupus erythematosus is believed to be independently associated with the risk of 
developing DVT.61 The odds ratio for DVT in patients with systemic lupus erythematosus, 
compared with those without it, was 4.3.61 
16.10 Behçet disease 
Behcet disease is a rare multisystem inflammatory disorder of unknown cause.213 VTE 
occurs in about one-fifth of patients with Behc¸ et disease.213 
16.11 Paroxysmal nocturnal hemoglobinuria 
Review of 13 retrospective studies of patients with paroxysmal nocturnal hemoglobinuria 
showed a 30% prevalence of venous thrombotic events in patients from Western nations.214 
The majority was within the hepatic and mesenteric veins.214 
16.12 Buerger disease 
PE associated with thromboangiitis obliterans (Buerger disease) is rare, and to our 
knowledge, limited to a case report.215 
17. Sepsis 
Initiation of coagulation takes place when TF is exposed, such as by fibroblasts, when there 
is tissue damage or by cytokine-stimulated monocytes and endothelial cells216, as in sepsis. 
While TF is the major initiator of coagulation, endotoxin, foreign bodies, and negatively 
charged particles may initiate coagulation via contact system activation. TF binds to factor 
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VIIa, and this complex (TF:VIIa) may then activate factor X and factor IX217. Factor Xa, 
associated with factor Va, forms the prothrombinase complex, which subsequently turns 
prothrombin into thrombin. 
The relationship between coagulation and inflammation is complex and, as yet, not 
completely understood. It is known that blood clotting not only leads to fibrin deposition 
and platelet activation, but it also results in vascular cell activation, which contributes to 
leukocyte activation218. On the other hand, inflammation can induce TF expression in 
monocytes, via nuclear factor kappa-B (NF-kB) activation, thus initiating coagulation216. 
Examples of this interaction are readily seen. First, leukocytes are found at relatively high 
concentrations in venous thrombi, and leukocytes and activated platelets can form rosettes 
mediated by P-selectin expression on the surface of the activated platelet 219,220. 
These microscopic observations are probably elicited from the actions of thrombin, which 
can activate platelets and endothelium, increasing the surface expression of P-selectin221,222. 
P- electin is the primary initial mediator of leukocyte-endothelial cell rolling and is critical 
for leukocyte adhesion. Second, TF:VIIa and factor Xa have been shown to activate cells and 
generate responses similar to those mediated by thrombin218. Third, GAG and TM 
expression on cell surfaces are inhibited by inflammatory cytokines 223,224,225,226 and 
lipopolysaccharide (LPS)227, thus blocking the augmentation of AT action by GAG, and APC 
formation by TM. 
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